Speakers: 

Alexis Fanshier, PharmD, PGY2 Hematology/Oncology Resident - has nothing to disclose.

Annum Hayat, MD, PGY4 Hematology/Oncology Fellow - has nothing to disclose.

Moderator: 

Tristan Maiers, PharmD, BCOP, PGY2 Oncology Residency Program Director, Geisinger - has nothing to disclose. 

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

1. Describe the pathophysiology and clinical presentation of multiple myeloma (MM).​​

2. Review the diagnosis, disease staging, and risk stratification systems for MM. ​​

3. Evaluate the mechanisms of action, dosing, dose-limiting toxicities (DLTs), and monitoring parameters of frontline treatment options for MM.​​

4. Apply guideline-directed medical therapy (GDMT) and current literature in treating MM.​

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Tristan Maiers, PharmD, BCOP; Rajiv Panikkar, MD; Michele Long, BSN; Jaime Weeder, NP and Christopher Kashi, PA-C have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPAA compliant. 

Commercial Support for this Session

None